News

‘Back to the Future’ Inspires Effort to Detect Parkinson’s in Its Earliest Phases

New research by the Leibniz-Institut für Molekulare Pharmakologie (FMP) aims to make possible the early detection of Parkinson’s disease (PD) by using strongly magnetized xenon gas to enhance magnetic resonance imaging (MRI) scans. The project, funded by a nearly $350,000 three-year award from the Michael J. Fox Foundation for Parkinson’s Research, was,…

Discovery of Factors Connecting Parkinson’s Disease with Alzheimer’s Opens Door for Developing New Treatments

Researchers have discovered a factor that controls the accumulation of both alpha-synuclein and tau, two proteins that drive neurodegeneration in Parkinson’s and Alzheimer’s diseases. The findings bring not only a new understanding of how the two conditions may be linked, but also offer possibilities for the development of new treatment…

Insights into Rare Disease May Lead to Novel Therapeutic Targets for Parkinson’s

The rare lysosomal storage disorder Krabbe’s disease is caused by an enzyme deficiency and has been found to have surprising similarities with neurodegenerative disorders, including Parkinson’s disease. Establishing this connection can be a valuable tool for developing novel therapeutic targets and new biomarkers for identifying patients at risk for developing Parkinson’s.

New Therapy for Parkinson’s ‘Off’ Periods Shows Promising Results in Preclinical Studies

CVT-301, an inhalable drug under development by Acorda Therapeutics to treat Parkinson’s symptoms during “off” periods when currently available drugs don’t adequately work, showed promising results in preclinical Phase 1 and 2 studies. Since the late 1960s, levodopa has been the most common and efficient oral drug used for managing Parkinson’s motor…

Patent Request Filed for Cannabis-based Treatments for Parkinson’s and Like Diseases

Growblox Sciences has filed the first of several likely patent applications for cannabis-based compounds developed by Growblox Life Sciences, its wholly owned subsidiary. The application applies to pharmaceutical-grade mixtures that might be used to treat patients with neurodegeneration, especially those with Parkinson’s disease. Growblox Life Sciences is focused on researching and developing cannabis-based medicines.  The company uses various…